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Abstract Thymocyte selection-associated high-mobility
group box (TOX) is aberrantly expressed in cutaneous
T-cell lymphomas. In a recent study, TOX expression was
noted unexpectedly in the follicle center (germinal center)
B-cells of reactive lymph nodes and tonsils, used as
external controls. To evaluate whether TOX is also
expressed by cutaneous B-cell lymphomas, TOX
immunohistochemistry was performed on skin biopsies of
44 patients with primary and secondary cutaneous B-cell
proliferations. TOX was expressed not only in the reactive
follicle center cells of lymph nodes, tonsils, cutaneous
lymphoid hyperplasia, and primary cutaneous marginal
zone lymphomas, but also by the neoplastic follicle center
cells of 16/17 patients with primary cutaneous follicle
center lymphoma (PCFCL) and 7/7 patients with cutaneous
manifestations of systemic follicular lymphoma (FL).
Notably, TOX showed a very similar expression pattern as
BCL6, a marker of germinal center B-cells. In 4/10 patients
with a BCL6? primary cutaneous diffuse large B-cell
lymphoma, leg type (PCDLBCL,LT) and in 2/2 patients
with a secondary cutaneous BCL6? diffuse large B-cell
lymphoma (DLBCL), TOX was expressed by more than
50 % of the neoplastic B-cells. In contrast, in 3/3 BCL6-
PCDLBCL,LT, TOX was completely negative or weakly
expressed by a minor proportion of the neoplastic B-cells.
In conclusion, TOX is expressed not only by neoplastic
T-cells, but also by both reactive and neoplastic follicle
center (germinal center) B-cells and a proportion of
BCL6? PCDLBCL,LT and secondary cutaneous BCL6?
DLBCL. The functional significance of TOX expression in
reactive and neoplastic B-cells remains to be elucidated.
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Introduction
In the past few years, TOX [thymocyte selection-associated
high-mobility group (HMG) box] has been described as a
potential new diagnostic marker for cutaneous T-cell
lymphoma (CTCL) [16]. TOX is a family member of HMG
box proteins and is involved in the regulation of gene
expression, as by modifying the density of the chromatine
structure [13]. In general, TOX is associated with the
development of CD4? T-cells in the thymus and is sub-
sequently downregulated in mature CD4? T-cells [1]. TOX
was also shown to be expressed in the development of
other lymphoid cells, such as lymphoid tissue inducer (LTi)
cells that normally act as key regulators of lymph node
organogenesis [2].
Recent studies showed aberrant expression of TOX in
different types of CTCL, mainly Se´zary syndrome (SS) and
mycosis fungoides (MF), but also in primary cutaneous
CD30? lymphoproliferative disorders, including primary
cutaneous anaplastic large cell lymphoma and lym-
phomatoid papulosis (LyP), though with lower intensity,
and cases of adult T-cell leukemia/lymphoma and periph-
eral T-cell lymphoma, not otherwise specified [4, 7, 8, 15].
Morimura et al. suggested that TOX expression is limited
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to CD4? T-cells in MF and SS, and CD30? T-cells in LyP
[8]. However, in a recent study of our own group, TOX was
also expressed by the neoplastic T-cells in the cases of MF
and other CTCL with CD4-CD8? or CD4-CD8- pheno-
types and by (intra-epidermal) CD8? T-cells in the cases of
atopic dermatitis [11]. Unexpectedly, expression of TOX
was also noted in follicular areas of reactive lymph nodes
and tonsils that were used as external controls. This
prompted us to further study TOX expression in various
types of cutaneous B-cell lymphoma (CBCL).
Materials and methods
Formalin-fixed and paraffin-embedded (FFPE) skin biop-
sies from 44 patients with primary or secondary cutaneous
B-cell proliferations were included: 17 patients with pri-
mary cutaneous follicle center lymphoma (PCFCL), 5
patients with primary cutaneous marginal zone lymphoma
(PCMZL), 13 patients with primary cutaneous diffuse large
B-cell lymphoma, leg type (PCDLBCL,LT), 7 patients
with skin manifestation of systemic follicular lymphoma
(FL), and 2 patients with skin manifestation of systemic
diffuse large B-cell lymphoma (DLBCL). FFPE tissue
samples of reactive lymph nodes and tonsils were included
as benign external controls. In addition, two cases of
cutaneous lymphoid hyperplasia (CLH; cutaneous pseudo
B-cell lymphoma) were evaluated. All diagnoses were
made by an expert panel of dermatologists and pathologists
at one of the regular meetings of the Dutch Cutaneous
Lymphoma Group, according to the classification system
of the World Health Organization (WHO) and the Euro-
pean Organization for Research and Treatment of Cancer
(EORTC) [14]. Therefore, sections from all biopsies were
routinely hematoxylin and eosin (H&E) stained with
additionally, depending on the differential diagnosis, a
selection of the following immunostainings: CD3, CD4,
CD5, CD8, CD10, CD20, CD21, CD23, CD30, CD35,
CD68, CD79a, CD138, PAX5, BCL2, BCL6, MUM1,
kappa, lambda, IgG, IgM, IgD, IgA, and/or Ki-67. In all
patients with diagnosis of a primary CBCL, staging pro-
cedures excluded extracutaneous disease. For the purpose
Fig. 1 Histopathology of a tonsil with reactive follicles. TOX (a) is
expressed in reactive follicles, predominantly in centrocytes (inset) in
a pattern similar to BCL6 (b), but also in some scattered lymphocytes
in the interfollicular areas (selected regions). (a, b 9100, selected
regions in a and b 9200 and inset in a 9400)
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of this study, all FFPE skin biopsies were collected from
the archives of the Department of Pathology, Leiden
University Medical Center (LUMC), Leiden, The Nether-
lands, and immunohistochemistry for TOX was performed
using Dako Autostainer Link 48 with rabbit anti-human
TOX antibodies of Sigma-Aldrich (HPA018322) in a
dilution of 1:200. The sections were evaluated by all
authors, and the percentage of TOX? cells was estimated
until consensus was reached. The intensity of TOX
expression was scored as dim or strong. The study was
performed in accordance with the Declaration of Helsinki
and the Dutch Code for Proper Secondary Use of Human
Tissue, approved by the medical ethics committee of the
LUMC.
Results
TOX expression in reactive lymph nodes, tonsils
and cutaneous lymphoid hyperplasia
In the reactive lymph nodes and tonsils that were used as
benign external controls, TOX was expressed in the fol-
licular areas and by scattered small lymphocytes, proba-
bly T-cells, in the interfollicular areas (Fig. 1). In the
follicular areas, the centrocytes showed moderate to
strong nuclear TOX expression, while staining of the
centroblasts was dim or absent. Serial sections showed
that the distribution of TOX? cells was very similar to
that observed for BCL6, a marker for germinal center
B-cells. The same expression pattern was observed in
both cases of CLH.
TOX expression in primary cutaneous follicle center
lymphoma and secondary cutaneous involvement
of systemic follicular lymphoma
TOX was expressed by the neoplastic follicle center cells
in 16/17 patients (94 %) with PCFCL and in 7/7 patients
(100 %) with skin lesions of systemic FL (Fig. 2). In these
cases, TOX and BCL6 also showed a very similar staining
pattern. Remarkably, in one case of PCFCL with a diffuse
growth pattern, the neoplastic follicle center cells were
positive for BCL6 but completely negative for TOX, while
TOX was expressed by scattered small lymphocytes,
serving as a useful internal control.
TOX expression in primary cutaneous marginal
zone lymphoma
In none of the five patients with PCMZL, TOX was
expressed by the marginal zone B-cells or the plasma cells.
In three patients, small reactive follicles were present that
showed TOX expression in a pattern as observed in reac-
tive follicles of lymph nodes and tonsils. In addition, TOX
was expressed by small scattered lymphocytes.
Fig. 2 Histopathology of a patient with primary cutaneous follicle
center lymphoma with a follicular growth pattern. Hematoxylin–eosin
staining (a) shows nodular dermal infiltrates of large centrocytes
(insets), which stain positively for BCL6 (b) and TOX (c). (a–c 9100,
and insets a–c 9400)
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TOX expression in primary cutaneous diffuse large
B-cell lymphoma, leg type and secondary cutaneous
involvement of systemic diffuse large B-cell
lymphoma
Thirteen patients with PCDLBCL,LT and two patients with
secondary cutaneous involvement of systemic DLBCLwere
evaluated. In general, approximately two-third of the
PCDLBCL,LT showed BCL6 expression in more than 50 %
of the neoplastic B-cells [12]. In our current series, 10/13
patients (79 %)with PCDLBCL,LTwere positive for BCL6.
Four of these cases (40 %) expressed TOX in more than
50 % of the neoplastic B-cells (Fig. 3). Intensity was strong
in 3/4 cases (75 %) and dim in 1/4 cases (25 %). In the other
six patients with a BCL6? PCDLBCL,LT and in the three
patients with a BCL6- PCDLBCL,LT, TOX was expressed
by a minor proportion of the neoplastic B-cells or was
completely negative. The two patients with secondary
cutaneous involvement of systemic DLBCL, both BCL6?,
showed either strong (n = 1) or weak (n = 1) TOX
expression inmore than 75 %of the neoplastic B-cells. In the
group of patients with PCDLBCL,LT, there was no rela-
tionship between expression of TOX and the clinical course
of the patients (data not shown).
Discussion
This study demonstrates that TOX is not only expressed by
neoplastic T-cells in CTCL, but also by follicle center cells
in all reactive follicles in lymph nodes, tonsils, CLH, and
PCMZL, and by neoplastic follicle center cells in 16/17
PCFCL, and 7/7 secondary cutaneous FL. In all these
cases, the staining pattern of TOX was very similar to that
of the follicle center cell marker BCL6. In addition, TOX
was expressed by 4/10 BCL6? PCDLBCL,LT and 2/2
BCL6? secondary cutaneous DLBCL, but not or only
weakly in a minority of the neoplastic B-cells in 3/3
BCL6- PCDLBCL,LT.
Currently, the literature on TOX in association with
B-cells is scarce. In developing B-cells, no TOX expression
was present, and mice deficient in TOX appeared to have
Fig. 3 Histopathology of a patient with primary cutaneous diffuse
large B-cell lymphoma, leg type. Hematoxylin–eosin staining
(a) shows diffuse infiltration of the dermis by sheets of CD20?
(b) centroblasts and immunoblasts with many mitotic and apoptotic
figures (inset in a). These blastic B-cells stain positive for BCL6
(c) and TOX (d) (a–d 9100, and insets a–d 9400)
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normally developed B-cells in the bone marrow and spleen
[1, 2]. In addition to the loss of CD4? T-cells, these mice
lacked normal development of lymph nodes and Peyer’s
patches. However, this was attributed to dysfunction of LTi
cells and not to dysfunction of B-cells [2]. Interestingly,
one study suggested that TOX is involved in germinal
center B-cell development and/or function, referring to a
study distinguishing subtypes of DLBCL by genetic pro-
filing, but further details were not provided [3, 9].
In CBCL, TOX expression has only been described to be
negative in PCDLBCL,LT, but the number of cases and
data on BCL6 expression were not provided [8]. In B-cell
lymphomas other than CBCL, TOX deletions, but not
expression, were detected in 3/45 patients (7 %) with pri-
mary central nervous system lymphomas, and in 2/126
patients (2 %) with acute lymphoblastic leukemia, of
which one had a B-precursor phenotype [5, 6, 10].
In conclusion, TOX is expressed not only by both
reactive and neoplastic T-cells, but also by both reactive
and neoplastic follicle center cells and a proportion BCL6?
PCDLBCL,LT and secondary cutaneous BCL6? DLBCL.
The functional significance of TOX expression in reactive
and neoplastic B-cells remains to be elucidated.
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